XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment
yahoo.com
news
2022-10-18 07:05:00

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its Rotigotine transdermal ("TDS") patch human skin cadaver study and dissolution data. The Company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor").

Further to the Company's product update on October 11, 2022, XPhyto is pleased to report excellent results from its recent Rotigotine TDS human cadaver skin absorption study.
